Receptors for human plasminogen on the biological response modifier OK-432

Journal of Biological Response Modifiers

Volumn 9, Issue 6, 1990, Pages 592-596

  Ullberg, Måns ^a   Tewodros, Wezenet ^a   Kronvall, Göran ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biological response modifiers; OK 432; Plasma proteins; Streptococcus

Indexed keywords

PICIBANIL; PLASMA PROTEIN; PLASMINOGEN;

ARTICLE; HUMAN; PRIORITY JOURNAL; RECEPTOR BINDING;

BLOOD PROTEINS; HUMAN; IN VITRO; PICIBANIL; PLASMIN; PLASMINOGEN; PROTEIN BINDING; RECEPTORS, CELL SURFACE; STREPTOCOCCUS PYOGENES; SUPPORT, NON-U.S. GOV'T;

EID: 0025647122     PISSN: 07326580     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Busch W. Über der Zürchting de erisipikokken und künstil-ichen nährboden und ihre übertragbarkeit auf dem menschen. Dtsch Med Wochenschr 1868;8:553-4.
2. Okamoto H. Experimental anticancer studies. Part XXX. Factors influencing the streptolysin-S forming ability of streptococci having anticancer activity. Jpn J Exp Med 1966;36:161-74.
3. Ishida N. Immunopotentiating activities of OK-432. Recent advances in the understanding of its mechanism of action. Tokyo: Excerpta Medica, 1986.
4. Wiman B, Rånby M. Determination of soluble fibrin in plasma by a rapid and quantitative spectrophotometric assay. Thromb Hemost 1986; 55:189-93.
5. Hojo H, Hashimoto Y. Cytotoxic cells induced in tumor-bearing rats by a streptococcal preparation (OK-432). Gann 1981;72:692-9.
6. Oshimi K. Streptococcal preparation OK-432 augments cytotoxic activity against an erythroleukemic cell line in human. Cancer Immunol Immunother 1980; 9:187-92.
7. Uchida A, Micksche M. Lysis of fresh tumor cells by autol-ogous peripheral blood and pleural effusion lymphocytes activated by OK-432. JNCI 1983;71:673-80.
8. Satio M. Action mechanism of OK-432 as a biological response modifier and its future prospect in cancer In: Ishida N, Klein G. eds. Host defence mechanisms and immunopo-tentiators-proceedings of a workshop at 14th International Congress of Chemotherapy. Tokyo: University of Tokyo Press, 1986:89-98.
9. Ishii Y, Yamaoka H, Toh K, Kikuchi K. Inhibition of tumor growth in vivo and in vitro by macrophages from rats treated with a streptococcal preparation. OK-432. Gann 1976;67: 115-9.
10. Saito M, Ebina T, Koi M, Yamaguchi T, Kawade Y, Ishida N. Induction of interferon-gamma in mouse spleen cells by OK-432, a preparation of Streptococcus pyogenes. Cell Immunol 1982;68:187-92.
11. Ichimura O. Lymphokine induction by streptococcal preparation, OK-432, in mice: characterization of IL-1, 1L-2 and NK activating factor (NKAF). In: Hoshino T, Uchida A, eds. Clinical and experimental studies in immunotherapy. Amsterdam: Excerpta Medica, 1984:48-70.
12. Urushizaki I, Niitsu Y, Watanabe N. Definition of tumor-necrosis factor and its production mechanism. Jpn J Cancer Chemother 1984;11:1356-68.
13. Vanky F, Uchida A, Klein E, Willems J. Lysis of autologous tumor cells by high-density lymphocytes is potentiated by the streptococcal preparation OK432 (picibanil). Int J Cancer 1986;37:531-6.
14. Micksche M. Experimental and clinical studies with OK-432. A streptococcal preparation with immunomodulation properties In: Serrou B, ed. Human cancer immunology. Amsterdam: Elsevier, 1982:31-54.
15. Kronvall G. A surface component of group A, C, and G streptococci with non-immune reactivity for immunoglobu-lin G. J Immunol 1973;11:1401-6.
16. Kronvall G, Schönbeck C, Myhre EB. Fibrinogen binding structures in beta hemolytic streptococci group A, C and G. Ada Pathol Microbio! Scand Sect B 1979;87:303-10.
17. Kronvall G, Myhre EB, Björk L, Berggård I. Binding of aggregated human beta-2-microglobulin to surface protein structure in beta hemolytic streptococci group A, C and G. Infect Immun 1978;22:136-42.
18. Köhler W, Prokop O. Relationship between haptoglobin and Streptococcus pyogenes T4 antigens. Nature (Lond) 1978; 271:373.
19. Myhre EB, Kuusela P. Binding of human fibronectin to A, C and G streptococci. Infect Immun 1983;40:29-34.
20. Kronvall G, Simmons A, Myhre EB, Jonsson S. Specific adsorption of human serum albumin, immunoglobulin A, and immunoglobulin G with selected strains of group A and G streptococci. Infect Immun 1979;25:1-10.
21. Müller H-P, Blobel H. Absorption of human alpha-2-macro-globulin with selected strains of streptococci. Infect Immun 1983;172:33-9.
22. Myhre EB, Kronvall G. Demonstration of specific binding sites for human serum albumin in group C and G streptococci. Infect Immun 1980;27:6-14.
23. Ullberg M, Kronvall G, Wiman B. New receptors for human plasminogen on gram positive cocci. APMIS 1989;97:996-1002.
24. Miles LA, Plow EF. Plasminogen receptors: ubiquitous sites for cellular regulation of fibnnolysis. Fibrinoiysis 1988;2:61-71.
25. Goldfarb RH, Liotta LA. Proteolytic enzymes in cancer invasion and metastasis. Semin Thromb Hemost 1986;12:294-307.
26. Marcus G. The relevance of plasminogen activators to neo-plastic growth. A review of recent literature. Enzyme 1988;40:158-72.
27. Marcus G. Plasminogen activators in malignant growth In: Davidson JF, Nilsson IM, Åstedt B, eds. Progress in fibrinoiysis, Vol. 6. Edinburg: Churchill Livingstone, 1983:587-604.
28. Agostino D, Cliffton EE. Decrease in pulmonary metastases: potentiation of nitrogen mustard effect by heparin and fibrinoiysis. Ann Surg 1963; 157:400-8.
29. Lo SK, Ryan TJ, Gilboa N, Lai L, Malik AB. Role of catalytic and lysine-binding sites in plasmin-induced neutrophil adherence to endothelium. J Clin Invest 1989;84:793-801.
30. Grau E, Moroz LA. Fibrinolytic activity of normal human blood monocytes. Thromb Res 1989;54:1-15.